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A B S T R A C T
In the last years tandem mass spectrometry (MS/MS) has become a leading technology used for neonatal
screening purposes. Newborn screening by MS/MS on dried blood spot samples (DBS) has one of its items in
methionine levels: the knowledge of this parameter allows the identiﬁcation of infant aﬀected by homocystinuria
(cystathionine β-synthase, CBS, deﬁciency) but can also lead, as side eﬀect, to identify cases of methionine
adenosyltransferase (MAT) type I/III deﬁciency.
We started an expanded newborn screening for inborn errors of metabolism in Campania region in 2007. Here
we report our ten years experience on expanded newborn screening in identifying patients aﬀected by hy-
permethioninemia. During this period we screened approximately 77,000 infants and identiﬁed two cases: one
case of classical homocystinuria and one patient aﬀected by defect of MAT I/III. In this paper we describe these
patients and their biochemical follow-up and review the literature concerning worldwide newborn screening
reports on incidence of CBS and MAT deﬁciency.
1. Introduction
Newborn screening (NBS) on dried blood spot samples (DBS), re-
cently performed by liquid chromatography (LC) linked to tandem mass
spectrometry (MS/MS), can occur during the ﬁrst few hours of a new-
born's life. It represents a complex screening system capable of de-
tecting several inborn errors of metabolism: LC-MS/MS, applied to NBS
programs, can detect> 70 diﬀerent metabolic diseases on a single DBS
collected in the ﬁrst hours from birth [1]. Methionine dosage is in-
cluded in this screening and it is leading to discovery new cases of
hypermethioninemia.
Methionine is metabolized by three isoforms of the enzyme Met
adenosyltransferase (MAT, EC 2.5.1.6) (Fig. 1). MAT I (tetrameric iso-
form) and III (dimeric isoform) are encoded by the same gene MAT1A
and are present mainly in adult liver. MAT II isoform, coded by MAT2A
gene, is negligible in adult liver but predominates in non-hepatic tissues
and fetal liver [2]. This enzyme is required for the synthesis of S-ade-
nosylmethionine (AdoMet), a methyl donor in cell reactions. S-adeno-
sylhomocysteine (AdoHcy), produced byAdoMet transmethylation is
then hydrolyzed by AdoHcy hydrolase (AHCY, EC 3.3.1.1) in homo-
cysteine (Hcy) [3]. Hcy, in turn, can be metabolized, by the vitamin
B12-dependent enzyme Met synthase (MS), to Met by accepting a me-
thyl group derived from the endogenous 5-methyltetrahydrofolate (5-
methyl-THF). Moreover, Hcy can be remethylated to Met by betaine-
Hcy-methyltransferase (BHMT) by using a methyl group from betaine, a
molecule derived from choline, forming N,N-dimethylglycine (DMG). In
an alternative pathway Hcy condensates with serine to form cy-
stathionine, a reaction catalysed by the vitamin B6-dependent enzyme
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cystathionine β-synthase (CBS, EC 4.2.1.22). Finally, cystathionine is
converted to α-ketobutyrate and cysteine by the γ-cystathionase in
another reaction requiring vitamin B6 (Fig. 1).
Hypermethioninemia may be consequence of various non-genetic
disorders as well as a variety of inborn errors of metabolism. Non-ge-
netic causes include liver disease, premature birth, and diet rich in
proteins. Some genetic diseases exhibit hypermethioninemia secondary
to generalized hepatic dysfunction: citrin deﬁciency, fumaryl acet-
oacetate hydrolase deﬁciency and mitochondrial depletion syndromes,
due to mutations in MPV17 or DGUOK genes. Causes of hypermethio-
ninemia involving primary defects in methionine metabolism include:
deﬁciencies of cystathionine β synthase (CBS), methionine adenosyl-
transferase type I and III, glycine N-methyltransferase (GNMT), cata-
lyzing the synthesis of N-methylglycine from glycine using AdoMet as
the methyl donor, and S-adenosylhomocysteine hydrolase. MAT I/III
deﬁciency leads to isolated hypermethioninemia [4], where the term
isolated identiﬁes elevated plasma Met levels without increase in Met
metabolites, although some patients with severe MAT I/III deﬁciency
have been reported to have plasma Hcy slightly elevated [5,6]. Con-
versely, in GNMT, AHCY, and CBS deﬁciencies hypermethioninemia
can be associated with the increase in some Met metabolites, including
AdoMet, AdoHcy, Hcy, and cystathionine. Another, unusual cause of
hypermethioninemia involves mutations in the gene for adenosine ki-
nase (ADK) [7]. ADK phosphorylates adenosine derived from hydrolysis
of S-adenosylhomocysteine by AHCY: in ADK deﬁciency, accumulation
of adenosine inhibits AHCY and this, in turn, arises the increase of S-
adenosylmethionine and methionine.
In May 2007 we started an expanded newborn screening for inborn
errors of metabolism in Campania region by analyzing amino acids,
amino acid ratios, acylcarnitines and acylcarnitine ratios in DBS sam-
ples using tandem mass spectrometry. Data from the pilot project be-
tween 2007 and 2014 period were previously reported [1]. We discuss
here in detail the cases of hypermethioninemia identiﬁed in our ten
years of screening experience (2007–2017); we also review the litera-
ture concerning worldwide newborn screening hypermethioninemia
reports.
2. Methods
2.1. Sample collection and diagnostic analysis
From January 2007 to June 2017 our NBS program screened,
through the LC-MS/MS analysis of amino acids and acylcarnitines in
DBS samples, approximately 77,000 newborns, between 48 and 72 h of
life. The newborn blood sample was obtained by heel prick and spotted
on a Schleicher & Schuell 903 grade ﬁlter paper sampling card
(Whatman, Dassel, Germany); for genetic analysis we collected 5mL of
blood from each infant. GC–MS analysis on urine was also performed.
Samples were prepared and analyzed as reported elsewhere [1,8].
Ethical approval: experimental protocols were according to guide-
lines approved by Italian Ministry of Health in the law 167 of August
19, 2016. For all patients informed consent was obtained from parents
for being included in the study.
3. Results
3.1. Worldwide newborn screening
According to data reported in the literature, in the last years some
hypermethioninemia cases were reported by MS/MS-based expanded
newborn screening program in USA, Mexico, Japan, Taiwan, Hong
Kong, China, Qatar, Australia, Spain, Portugal and Italy and are sum-
marized in Table 1.
Some studies have been reported on diﬀerent USA NBS programs. A
pilot study performed from 1992 through 1999 in Pennsylvania, Ohio,
North Carolina, reported 4 cases of hypermethioninemia, without fur-
ther characterization (approximately 1:175000) [9]. A study conducted
at The Children's Hospital of Philadelphia from 2000 to 2013 revealed
62 newborns with elevated methionine and identiﬁed 12 cases of
classical homocystinuria (cystathionine β-synthase deﬁciency) and 13
individuals aﬀected by MATI/III deﬁciency (incidence not available)
[10]. NBS among North Carolina population from 1997 through 2005
evidenced 2 cases of cystathionine β-synthetase deﬁciency (1:470,000)
[11]. Six other cases of homocystinuria (1:369,054) were reported by a
2001–2006 NBS program in California, Massachusetts, North Carolina,
and Wisconsin [12]. Finally, Zytkovicz et al. [13] reported an addi-
tional patient with hypermethioninemia in New England by a two years
screening program (1257000); no information was available con-
cerning the genetic basis of the biochemical alteration.
A pilot study performed in Mexico from March 2002 through
February 2004 among 42,264 screened newborns identiﬁed only one
patient as aﬀected by CBS deﬁciency [14].
Based on newborn screening data collected between 1992 and 2012
in Japan, 24 patients showing persistent hypermethioninemia had
Fig. 1. Metabolism of cobalamin and methionine.
Methylcobalamin (MeCbl) is the cofactor of the re-
action catalysed by the methionine synthase.
Methionine is metabolized by Met adenosyl-
transferase (MAT I/III) which catalyzes the synthesis
of S-adenosylmethionine (AdoMet). S-adenosylho-
mocysteine (AdoHcy), produced by AdoMet trans-
methylation is hydrolyzed by AdoHcy hydrolase
(AHCY) in homocysteine (Hcy) which, in turn, can
be metabolized, by the vitamin B12-dependent en-
zyme Met synthase (MS), to Met. Hcy can be also
remethylated to Met by betaine-Hcy-methyl-
transferase (BHMT). Alternatively, Hcy condensates
with serine to form cystathionine, a reaction cata-
lysed by the vitamin B6-dependent enzyme cy-
stathionine β-synthase (CBS) to be ﬁnally converted
to α-ketobutyrate and cysteine by the γ-cystathio-
nase.
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genetic diagnosis of MAT I/III deﬁciency with an estimated incidence of
1 in 107,850 [15].
In Taiwan two patients with hypermethioninemia (without in-
formation on the genetic basis of the alteration) were reported by
Huang et al. [16] as identiﬁed by an expanded newborn screening
program performed on 199,922 newborns from 2001 to 2004
(1:99961), conﬁrming the results obtained from neonatal screening for
homocystinuria in that region (1 case of CBS deﬁciency, 1:1701591,
and 16 cases of MATI/III deﬁciency, 1:106350; total incidence:
1:100094) [17]. A three year-journey in Hong Kong recently reported
one patient with hypermethioninemia due to MAT deﬁciency (1:30448)
[18]. In China a pilot study screened 371,942 neonates, identifying 98
cases of inborn errors of metabolism; among these three were patients
aﬀected by homocystinuria (1:123,981) [19].
Between 2003 and 2006 an extended neonatal screening performed
on 25,214 newborns of Qatar population evidenced 19 cases with me-
tabolic diagnosis; among these, two were newborn with hypermethio-
ninemia due to cystathionine β-synthase deﬁciency (1:12,607) [20].
In Australia a 5 years study on 461,500 newborns screened from
1998 to 2002 reported 2 patients aﬀected by CBS deﬁciency, ac-
counting for a prevalence of 1:230,750 [21].
Concerning the Iberian peninsula, NBS performed from 2000
(Spain) or 2004 (Portugal) to 2013 resulted in the identiﬁcation of three
patients with classical homocystinuria and 49 patients with MAT I/III
deﬁciency. Among these, thirty-one cases of MAT I/III deﬁciency
(1:27,400) and two cases of classical homocystinuria (1: 425,000) were
identiﬁed in Portugal, conﬁrming previous data (Martins et al., 2012),
while 18 cases of MAT I/III deﬁciency (1:22,874) and one classical
homocystinuria were detected in Spain (1:374,000). All the cases of
persistent isolated hypermethioninemia were due to mutations in the
MAT1A gene [22,23].
In Italy, two cases of Methionine adenosyltransferase deﬁciency
were reported by the NBS program performed in Tuscany region on
400,000 infants (1:200,000) [24]. Messina et al. recently reported the
results from 7 years of NBS program in Sicily: among 60,408 newborn
they identiﬁed one case of MATI/III deﬁciency [25]. One infant aﬀected
by cystathionine β-synthase deﬁciency was previously detected in
Campania region by our laboratory in a pilot study (1:45,466) [1]. In
the present paper we report a case of hypermethioninemia due to
MATI/III deﬁciency (1:77000) and updated also the CBS deﬁciency
incidence to 1:77000.
3.2. Hypermethioninemia case reports and follow up
Patient 1: This patient was previously reported [1]; here we de-
scribe his biochemical and clinical follow-up. Brieﬂy, at newborn
screening, patient 1 showed high concentration of methionine on DBS
(81 μMol/L; R.V.: < 20); at one month from birth also serum homo-
cysteine concentration showed to be elevated (107.3 μMol/L; R.V.:
5–15) associated to methionine levels of 61 μMol/L (Fig. 2). The dosage
of urinary organic acids showed a normal proﬁle; therefore, classical
homocystinuria was suspected (Table 2). Waiting for the genetic test
results, patient 1 was administered with folic acid (5mg/die) and vi-
tamin B6 (100mg/die). At two months from birth patient 1 showed fair
general conditions but generalized hypotonia associated to Hcy levels
of 122 μMol/L. Given the mild response to therapy, the B6 dosage was
increased to 300mg/die associated to 550mg/die betaine, and a low
methionine diet was started. From molecular analysis of the CBS gene
the patient resulted to be homozygous for the missense mutation
c.346G > A (p.G116R) in exon 5, previously reported to cause cy-
stathionine β-synthase deﬁciency. Patient's parents showed to be het-
erozygous for this same mutation. The biochemical follow-up of the
patient 1 showed signiﬁcant increase of serum methionine levels since
3months from birth, with the most relevant level at six months (1339
μMol/L); at 2 years of age methionine concentration was 764 μMol/L
(Fig. 2) while homocysteine levels was of 30 μMol/L; at this age a slightTa
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deﬂection of the growth curve was also noted, then ascribed to gas-
troenteric infection due to Helicobacter Pylori. In the following years
methionine levels remained substantially unchanged, while Hcy levels
slightly decreased to 22 μMol/L. Despite the high levels of methionine
patient 1 so far presents with good general clinical conditions, with a
normal psychomotor development.
Patient 2: at screening on DBS this patient showed a signiﬁcant
increase of methionine both for the ﬁrst and the second spot (42 and 88
μMol/L, respectively; R.V.: < 20). At birth sporadic tremors were re-
ported. At one and three months of birth the dosage of amino acids on
serum conﬁrmed the high levels of methionine (494 and 604 μMol/L,
respectively; R.V.: 9–42) (Fig. 2) associated to normal amounts of
homocysteine; the dosage of urinary organic acids exhibited a normal
proﬁle (data not shown). These results suggested the possibility that the
patient was aﬀected by isolated hypermethioninemia (Table 2): indeed,
molecular analysis identiﬁed, in heterozygosis, the mutation
c.791G > A on exon 7 of MAT1A gene (p.R264H); this variant, af-
fecting the intersubunit salt-brige formation, is known to be associated
to a dominant form of defect of Methionine Adenosyl Transferase [30]
and conﬁrmed the diagnosis of isolated hypermethioninemia due to
defect of MAT I/III. At three moths of birth the patient started a diet
with low amounts of methionine that led to a signiﬁcant decrease of
serum methionine levels (151 μMol/L at six months from birth); when
the patient was 1 year old his mother suspended the diet, nevertheless
methionine concentration further lowered (50 μMol/L at 12months
from birth) (Fig. 2), while at two years from diagnosis the follow up of
the patient showed a slight increase of serum Met levels (133 μMol/L).
At present patient 2 exhibits good general condition without signiﬁcant
clinical problems.
4. Discussion
Hypermethioninemia is a biochemical condition, characterized by
abnormal serum levels of amino acid methionine, rarely reported by
extended newborn screening programs. The increase of methionine
levels can be a consequence of primary defects in methionine meta-
bolism among which the most frequent are deﬁciency of cystathionine
β synthase and deﬁciency of methionine adenosyltransferase type I and
III. Due to the involvement of CBS in the metabolism of homocysteine,
in CBS deﬁciency hypermethioninemia is accompanied by hyperho-
mocysteinemia (and homocystinuria), while MAT deﬁcient patients
usually exhibit just increased levels of methionine. Extended newborn
screening by MS/MS has one of its items in DBS methionine levels while
homocysteine is not a primary newborn screening marker in most of the
NBS programs; therefore, ﬁnding of increased levels of met at NBS is
followed by dosage of serum Hcy levels to help to distinguish the
pathologies of methionine metabolism.
CBS deﬁciency (OMIM #236200), also known as classical homo-
cystinuria, is an autosomal recessive pathological condition with high
clinical heterogeneity: it can be asymptomatic but frequently is char-
acterized by myopia, thromboembolic events, skeletal anomalies
(marfanoid features) and neurological problems. Real incidence of
CBSD is not yet known: the estimated world-wide frequency is
1:344000, while in Europe higher frequencies are suggested (1:100000)
[26]. Concerning the incidence reported by MS/MS-base extended NBS
programs, our reviewing of the literature evidences values between
1:12607 and 1:470000, with the highest frequency ascribed to Qatar
and the lowest frequency present in USA. In Italian Campania region
the results from our NBS program allowed to estimate an incidence of
1:77000, that is close to the above reported estimated European fre-
quency. CBSD presents with two phenotypic variants: B6-responsive
homocystinuria, usually associated to p.Ile278Thr mutation, and B6-
Fig. 2. Follow-up of the methionine levels of the newborns aﬀected by hypermethioninemia.
Follow-up of serum methionine levels of the patient aﬀected by CBS deﬁciency (patient 1) and of the patient aﬀected by MAT I/III deﬁciency (patient 2).
Table 2
diﬀerential diagnosis for the hypermethioninemia.
Disease Primary alterations Main secondary alterations Second level alterations
Cystathionine beta-synthase deﬁciency Methionine ↑ Homocysteine ↑
Isolated hypermethioninemia (MAT def.) Methionine ↑
GNMT deﬁciency Methionine ↑ S-adenosyl-methionine ↑
AHCY deﬁciency S-adenosyl-methionine ↑ Methionine ↑
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unresponsive variant, frequently caused by p.Gly307Ser alteration [27].
NBS programs using Met as primary marker are suggested to under-
estimate B6-responsive diseases, since this milder patients can have
slightly increased levels of methionine when screened [3]. Indeed, our
screening program identiﬁed only one case of CBSD among approxi-
mately 77,000 screened infants and this patient harbored in homo-
zygosity a mutation, p.G116R, previously reported in patients aﬀected
by pyridoxine non-responsive homocystinuria [28]. Accordingly, this
patient was substantially unresponsive to vitamin B6 administration.
Nevertheless, this patient until now evidenced good general clinical
conditions with normal psychomotor development.
MAT I/III deﬁciency (OMIM 250850) usually results in isolated
persistent hypermethoninemia. In most cases MAT I/III deﬁciency
presents with mild or no clinical sign; however a small number of pa-
tients develop clinical manifestations, in particular neurological pro-
blems associated with brain demyelination (subnormal IQ, tremor,
dystonia, language and learning diﬃculties) [29]. Also for this pa-
thology the true incidence is unknown; however, the results reported by
diﬀerent MS/MS-based NBS programs show an especially high in-
cidence in the Iberian Peninsula (1:22874–1:27400) and a relatively
low rate in Japan (1:107850). In Italy, the incidence appears to be
higher in southern regions (Campania and Sicily), while this pathology
is more rarely reported in screening programs working in the north of
the peninsula (Table 1). MAT I/III deﬁciency is an autosomal pathology
that can be recessive or dominant, depending on the mutations af-
fecting the MAT1A gene. In fact, since the active MAT protein exists as
dimeric or tetrameric forms, it can be prone to the dominant negative
eﬀect of some alterations. The most common autosomal dominant form
of MAT deﬁciency is due to the presence, in heterozygosity, of mutation
p.R264H which dominant negative eﬀect is related to the importance of
264 codon for the dimerization of the functional protein [29]. This
alteration has been reported in diﬀerent populations but is especially
frequent in the Iberian Peninsula [22] and is the mutation found in our
patient 2. This alteration allows a signiﬁcant residual MAT enzyme
activity and is usually associated to moderate blood levels of methio-
nine in patients with benign clinical course [30]. Accordingly, our pa-
tient was asymptomatic during a 2-years follow-up and presented, also
in absence of diet therapy, moderate levels of serum methionine and
normal clinical conditions.
In conclusion, during ten years of MS/MS-based newborn screening
we identiﬁed in Campania region only two cases of hypermethioni-
nemia, one due to CBS deﬁciency and one due to MAT I/III deﬁciency.
Indeed, false negative cases are still possible, due to laboratory errors,
low levels of methionine in the ﬁrst days of life or cut oﬀ values too
high; however, we have no news from clinicians of our structures
concerning cases of CBSDD or MAT deﬁciency escaped our control and
we are conﬁdent that the incidence we found for these pathologies is
trusted for the screened population. Moreover, we are going to imple-
ment a send-tier test for total homocysteine on DBS to approach, at
newborn screening, the unequivocal diagnosis for MAT deﬁciency and
classical homocystinuria. Both our patients were substantially asymp-
tomatic until 2 years from birth; however, since also for MAT I/III de-
ﬁciency due to p.R264H mutation rare cases with myelination disorder
have been reported [31] a careful clinical monitoring will be continued.
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